HUTCHMED (China) Limited (FRA:H7T1)

Germany flag Germany · Delayed Price · Currency is EUR
11.90
0.00 (0.00%)
At close: Dec 4, 2025
-26.99%
Market Cap 2.10B
Revenue (ttm) 512.77M
Net Income (ttm) 397.55M
Shares Out n/a
EPS (ttm) 0.45
PE Ratio 5.27
Forward PE 11.02
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 1
Open 11.90
Previous Close 11.90
Day's Range 11.90 - 11.90
52-Week Range 10.40 - 16.80
Beta n/a
RSI 40.78
Earnings Date Nov 19, 2025

About HUTCHMED (China)

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ... [Read more]

Industry Pharmaceutical Preparations
Founded 2000
Employees 1,811
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol H7T1
Full Company Profile

Financial Performance

In 2024, HUTCHMED (China)'s revenue was $630.20 million, a decrease of -24.80% compared to the previous year's $838.00 million. Earnings were $37.73 million, a decrease of -62.56%.

Financial numbers in USD Financial Statements

News

There is no news available yet.